Core Argument - The prevailing aging models inadequately address the role of persistent pathogens (viruses, bacteria, parasites) as a significant driver of human aging and healthspan reduction [1] - Persistent pathogens can embed themselves in tissues and nerves, potentially driving various health problems later in life [2][3][4] - These pathogens can actively distort the signaling of human genes, impacting multiple hallmarks of aging [8] Pathogen Prevalence and Impact - Approximately 95% of individuals harbor one or more strains of herpes virus [5] - Around 11% of people in the US and up to 87% in some global regions carry the chronic parasite toxoplasma [6] - Persistent SARS-CoV-2 virus has been found in tissue samples months or years after initial infection [7] - Pathogens can drive mitochondrial dysfunction by hijacking host cell metabolism [10][11][12] - Viruses can integrate into telomeres, leading to shorter and more unstable telomeres [13][14] - Viral proteins can interact with and distort the signaling of human aging pathways [15] Proposed Solutions and Recommendations - The industry needs to seriously consider the impact of persistent pathogens when developing healthspan extending interventions [17] - Curbing the activity of pathogens should precede interventions like gene editing [18] - Integrating existing antiviral and anti-parasite medications into healthspan protocols is recommended [18] - Individuals with herpes simplex virus who regularly took anti-herpes virus medications had a 10 times lower risk of developing dementia [19] - Investment in new diagnostic test platforms to identify persistent pathogens is crucial [20][21] - Incorporating the activity of persistent pathogens into aging models is essential for successfully extending healthspan [22]

Financial Performance & Growth - Q2 2025 total test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased by 33% year-over-year compared to Q2 2024[14, 61] - Gross Margin for Q2 2025 was 77%, while Adjusted Gross Margin reached 80%, slightly lower than the 81% and 83% respectively in the same period of 2024[14] - Net cash provided by operations in Q2 2025 was $20.8 million, a decrease from $24.0 million in Q2 2024[14] - As of June 30, 2025, the company's cash, cash equivalents, and marketable investment securities totaled $275.9 million[14] - Net income for Q2 2025 was $4.5 million, and Adjusted EBITDA was $10.4 million[14] Strategic Initiatives - The company aims to achieve operating cash flow positivity by the end of 2025[4, 60] - The company closed its acquisition of Previse, a gastrointestinal health company, focusing on chronic acid reflux related diseases, including esophageal cancer[14] - The company entered into a collaboration and license agreement with SciBase to develop diagnostic tests for dermatologic diseases[14] Market Penetration & Clinical Utility - DecisionDx-Melanoma clinical use is associated with improved patient survival, with a 29% lower 3-year melanoma-specific mortality and a 17% lower 3-year overall mortality in tested patients compared to untested patients[38] - DecisionDx-SCC Class results predict an SCC patient's individual metastatic risk and individual benefit of ART[44] - TissueCypher is the strongest independent predictor of progression to HGD or EAC in Barrett's esophagus patients, detecting 62% of progressors[51, 52]